Aleš Obreza

908 total citations
33 papers, 733 citations indexed

About

Aleš Obreza is a scholar working on Organic Chemistry, Molecular Biology and Spectroscopy. According to data from OpenAlex, Aleš Obreza has authored 33 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Organic Chemistry, 13 papers in Molecular Biology and 6 papers in Spectroscopy. Recurrent topics in Aleš Obreza's work include Synthesis and Characterization of Heterocyclic Compounds (7 papers), Chemical Synthesis and Analysis (5 papers) and Click Chemistry and Applications (5 papers). Aleš Obreza is often cited by papers focused on Synthesis and Characterization of Heterocyclic Compounds (7 papers), Chemical Synthesis and Analysis (5 papers) and Click Chemistry and Applications (5 papers). Aleš Obreza collaborates with scholars based in Slovenia, Switzerland and France. Aleš Obreza's co-authors include Zdenko Časar, Slavko Pečar, Stanislav Gobec, Marjan Bele, Stane Srčič, U. Urleb, Mojca Stegnar, Didier Blanot, Andreja Kovač and Rok Frlan and has published in prestigious journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Aleš Obreza

32 papers receiving 701 citations

Peers

Countries citing papers authored by Aleš Obreza

Since Specialization

Citations

This map shows the geographic impact of Aleš Obreza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleš Obreza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleš Obreza more than expected).

Fields of papers citing papers by Aleš Obreza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aleš Obreza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleš Obreza. The network helps show where Aleš Obreza may publish in the future.

Co-authorship network of co-authors of Aleš Obreza

This figure shows the co-authorship network connecting the top 25 collaborators of Aleš Obreza. A scholar is included among the top collaborators of Aleš Obreza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aleš Obreza. Aleš Obreza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase: A new approach for the treatment of Alzheimer's disease 2024 ·Pharmacology & Therapeutics ·(unknown), Damijan Knez, Aleš Obreza, Urban Košak, Stanislav Gobec	2
2	Design and synthesis of amino-substituted N-arylpiperidinyl-based inhibitors of the (immuno)proteasome 2023 ·Acta Pharmaceutica ·Martina Gobec, Aleš Obreza, Marko Jukič, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Izidor Sosič	1
3	A Putative Serine Protease is Required to Initiate the RIPK3-MLKL—Mediated Necroptotic Death Pathway in Neutrophils 2021 ·Frontiers in Pharmacology ·Xiaoliang Wang, (unknown), Aleš Obreza, Shída Yousefi, Irena Mlinarič‐Raščan, Hans‐Uwe Simon	8
4	Development and Optimization of Liquid Chromatography Analytical Methods by Using AQbD Principles: Overview and Recent Advances 2019 ·Organic Process Research & Development ·(unknown), (unknown), Zdenko Časar, Aleš Obreza	148
5	Curriculum Mapping of the Master’s Program in Pharmacy in Slovenia with the PHAR-QA Competency Framework 2017 ·SHILAP Revista de lepidopterología ·(unknown), Nejc Horvat, Mitja Kos, Aleš Obreza, Tomaž Vovk, Iztok Grabnar, Borut Božič	5
6	Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment 2014 ·Cancer Immunology Immunotherapy ·Urban Švajger, Martina Gobec, Aleš Obreza, Irena Mlinarič‐Raščan	2
7	Selective Cytotoxicity of Amidinopiperidine Based Compounds Towards Burkitt’s Lymphoma Cells Involves Proteasome Inhibition 2012 ·PLoS ONE ·Martina Gobec, Aleš Obreza, (unknown), Boris Brus, Stanislav Gobec, Irena Mlinarič‐Raščan	7
8	Influence of different types of commercially available microcrystalline cellulose on degradation of perindopril erbumine and enalapril maleate in binary mixtures / Vpliv različnih tipov komercialno dostopne mikrokristalne celuloze na razpad erbuminijevega perindoprilata in enalaprilijevega maleata v binarnih zmeseh 2012 ·Acta Pharmaceutica ·(unknown), (unknown), Odon Planinšek, Aleš Obreza	13
9	The efficient synthesis of amphiphilic oximes of galactose and glucosamine 2012 ·Tetrahedron Letters ·Janez Mravljak, Aleš Obreza	1
10	Review of operating principle and applications of the charged aerosol detector 2010 ·Journal of Chromatography A ·(unknown), Aleš Obreza	152
11	A New Approach for Increasing Ascorbyl Palmitate Stability by Addition of Non-irritant Co-antioxidant 2010 ·AAPS PharmSciTech ·(unknown), Aleš Obreza, Slavko Pečar, Mirjana Gašperlin	13
12	Azaphenylalanine-based serine protease inhibitors induce caspase-mediated apoptosis 2008 ·European Journal of Pharmacology ·Teja Celhar, Tina Batista Napotnik, Aleš Obreza, Anamarija Zega, Marko Anderluh, D. Kikelj, Irena Mlinarič‐Raščan	5
13	Design, synthesis and molecular modelling of 1-amidinopiperidine thrombin inhibitors. 2007 ·PubMed ·(unknown), Andrej Perdih, Mojca Stegnar, (unknown), Tomaž Šolmajer, U. Urleb, Aleš Obreza	3
14	Direct thrombin inhibitors built on the azaphenylalanine scaffold provoke degranulation of mast cells 2006 ·Thrombosis and Haemostasis ·(unknown), (unknown), Anamarija Zega, Aleš Obreza, Marko Oblak, Gorazd Drevenšek, (unknown), (unknown), U. Urleb, Luka Peternel	4
15	Recent Advances in Design, Synthesis and Biological Activity of Aminoalkylsulfonates and Sulfonamidopeptides 2004 ·Current Medicinal Chemistry ·Aleš Obreza, Stanislav Gobec	33
16	Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method 2004 ·International Journal of Pharmaceutics ·(unknown), Aleš Obreza, Marjan Bele, Stane Srčič	90
17	Novel Non‐Covalent Azaphenylalanine Thrombin Inhibitors with an Aminomethyl or Amino Group at the P1 Position 2004 ·ChemInform ·Aleš Obreza, Mojca Stegnar, U. Urleb	6
18	Novel non-covalent azaphenylalanine thrombin inhibitors with an aminomethyl or amino group at the P1 position. 2004 ·PubMed ·Aleš Obreza, Mojca Stegnar, U. Urleb	6
19	Abuse of Clenbuterol and its Detection 2003 ·Current Medicinal Chemistry ·(unknown), Aleš Obreza, Slavko Pečar	72
20	A Two-Step Synthesis of Hexahydropyrrolo-[1,2-d][1,2,4]triazine-1,4-dione and Related Compounds 2003 ·Synthetic Communications ·Aleš Obreza, U. Urleb	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact